BACOM 2.0 facilitates absolute normalization and quantification of
  somatic copy number alterations in heterogeneous tumor by Fu, Yi et al.
Genome analysis 
BACOM 2.0 facilitates absolute normalization and quantification 
of somatic copy number alterations in heterogeneous tumor   
Yi Fu1, Guoqiang Yu1, Douglas A. Levine2, Niya Wang1, Ie-Ming Shih3, Zhen Zhang3,        
Robert Clarke4 and Yue Wang1 
1Department of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, VA 
22203, USA; 2Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA; 3Departments 
of Pathology and Oncology, Johns Hopkins University, Baltimore, MD 21231, USA; 4Lombardi Comprehensive Cancer Cen-
ter, Georgetown University, Washington, DC 20057, USA 
 
Contact: yuewang@vt.edu  
Supplementary information: Supplementary data and discussion 
are available at Bioinformatics online.  
1 INTRODUCTION  
In the November 2011 issue, Yu et al. proposed a Bayesian analysis 
of copy number mixtures (BACOM) method to detect genomic de-
letion types and to correct normal cell contamination in copy num-
ber data (Yu, et al., 2011). They tested BACOM method on two sim-
ulated and two prostate cancer datasets, and obtained very promising 
results supported by the ground truth and biological plausibility 
(Zhang, et al., 2014). In a subsequent analysis of TCGA ovarian can-
cer dataset, the average normal cell fraction estimated by BACOM 
was found higher than expected. In this letter, we first discuss the 
advantages of BACOM method in relation to alternative approaches 
(Carter, et al., 2012; Rasmussen, et al., 2011; Su, et al., 2012; Yuan, 
et al., 2012). Then, we show that this elevated estimate of normal 
cell fraction is the combined result of incorrect signal normalization 
and parameter estimation. Lastly, we describe an allele-specific ab-
solute normalization and quantification scheme that can enhance 
BACOM applications in many biological contexts (Kuhn, et al., 
2012; Liu, et al., 2009). An open-source MATLAB software is de-
veloped to implement BACOM 2.0 and is publically available. 
2 EXTENDED METHOD 
2.1 BACOM overview 
BACOM is a statistically principled and unsupervised method that detects 
copy number deletion types (homozygous versus heterozygous), estimates 
normal cell fraction, and recovers cancer-specific copy number profiles, us-
ing allele-specific copy number signals. In a heterogeneous tumor sample, 
the measured copy number intensity is a mixture of the signals from both 
normal and cancer cells,  
normal, cancer, ,            (1 ) (1)α α= × + − ×i i iX X X                  
where iX  is the observed copy number signal at locus i , α is the unknown 
fraction of normal cells, normal,iX  and cancer,iX  are the latent copy number 
signals in normal and cancer cells at locus i , respectively. Let  ,A iX  and 
,B iX  be the allele-specific copy number signals, , ,i A i B iX X X= +  are 
assumed to be independently and identically distributed random variables 
following a normal distribution 2( , )A B A Bµ σ+ +  whose mean A Bµ +  and var-
iance 2A Bσ +  can be readily estimated by the sample averages. Allele-spe-
cific analyses are focused on the deletion regions with distinct genotypes. 
Types of deletions are detected by a model-based Bayesian hypothesis test-
ing. Specifically, BACOM uses a novel summary statistic, 
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where 2A Bσ −  is the variance of , ,A i B iX X−  in a length-L deletion re-
gion. It has been shown that under homo-deletion, Y  follows an L  de-
grees of freedom standard 2χ  distribution, given by  
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and under hemi-deletion, Y  follows an L  degrees of freedom noncentral 
2χ distribution, given by    
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where ( ) ( ) ( )2 22 1 1A B A BLλ µ σ ρ ρ−+ += − + − , ρ  is the genuine cor-
relation coefficient between ,A iX  and ,B iX , and Γ  denotes the Gamma 
function. Since for a deletion region, we have 
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then, the average normal cell fraction α  across the whole genome can be 
estimated, as well as cancer-specific copy number profiles, given by  
[ ] [ ]cancer, homo hemi2ˆ , with , = 1,       (6)
1 2
α
α α
α
−
= = −
−
ii
i i
E XXX E X   
2.2 Problem diagnosis 
In our independent analyses of TCGA samples with BACOM, we confirmed 
unexpectedly higher average normal cell fractions. By a closer check on the 
interim results of the entire BACOM analytic pipeline, we found that many 
normal/amplified copy regions and hemi-deletions were misclassified as 
homo-deletions. This observation explains well the suspected overestimation 
of normal cell fraction, since α will be overestimated when non-deletion re-
gions are wrongly used in (6), or αhomo is applied to hemi-deletions (αhomo > 
αhemi). We thus argue that this elevated estimate is the combined result of 
incorrect signal modeling and normalization, particularly in the presence of 
copy-neutral loss of heterozygosity (LOH) and aneuploidy. For example, if 
a non-deletion region is firstly misclassified as deletion due to incorrect sig-
nal normalization, it can be further misclassified as homo-deletion in the 
cases of allelic balance. Moreover, if the value of ρ is firstly underestimated 
due to copy-neutral LOH (allelic-imbalance) contamination in normal/al-
lelic-balanced regions, hemi-deletion will then be misclassified as homo-de-
letion caused by much reduced signal-to-noise ratio.  
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More detailed reasoning on the root causes of the underestimated tumor 
purity by BACOM method are given in Supplementary Information. 
2.3 BACOM 2.0: Allele-specific absolute normaliza-
tion and quantification 
Accurate signal normalization essentially rescales the relative signal intensi-
ties on the basis of normal copy regions (diploid reference loci), here termed 
as absolute normalization (Attiyeh, et al., 2009; Popova, et al., 2009). As the 
intertwined result of normal cell contamination, copy number aberrations, 
and tumor aneuploidy, the average ploidy of tumor cells cannot be assumed 
to be 2N or integer (Rasmussen, et al., 2011). Though absolute normalization 
is critical to inferring absolute copy numbers in a tumor sample, the classic 
normalization procedure based on median-centering of the total probe inten-
sities is problematic (Carter, et al., 2012; Wang, et al., 2002; Yu, et al., 2011), 
since the dominant component of the intensity mixture distribution rarely 
coincides with the normal copy number ‘2’ (Rasmussen, et al., 2011).  
Let us consider histogram modeling of genome-wide copy number signals. 
Based on underlying signal characteristics, we adopt a mixture of K Gaussian 
distributions (Attiyeh, et al., 2009), given by  
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where kπ  is the relative proportion of the k-th copy number component and 
g(.|.) is the Gaussian kernel with ( )2,k kµ σ  being the mean and variance. 
Such mixtures can be estimated from observed histogram using soft cluster-
ing or maximum likelihood method. However, our experimental studies on 
real tumor data confirmed that the component mean with the largest kπ  does 
not always correspond to the mean of normal copy regions, probably due to 
aforementioned factors, and thus cannot serve as the baseline for absolute 
normalization. While we have also observed that the largest component(s) 
often resides within the neighborhood of normal copy component.  
Thus, we first develop an effective scheme to eliminate the loci belonging 
to the hemi-deletions (with copy number ‘1’) and the allelic-imbalanced re-
gions (with copy number ‘3’, ‘5’, etc.). Specifically, we use a sliding window 
centered at a locus to estimate the between-allele correlation coefficient and 
remove those loci whose correlation coefficients are lower than an automat-
ically-determined threshold value, since the imbalanced allele signals asso-
ciated with odd copy numbers would produce a sufficiently negative value 
of ρ, given by (in the case of copy number ‘3’) 
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where σ2 is the variance of noise and ρ0 is the genuine between-allele corre-
lation coefficient. It is worth noting that this procedure also eliminates copy-
neutral LOH loci and thus can improve the accuracy of estimating ρ by using 
only normal copy loci. It can be shown that, copy-neutral LOH contamina-
tion will result in an inaccurate estimate of ρ, given by 
  
( )
( )
2
LOH-contaminated 2 2
                        (1,
1
9)
1 ρ σ
ρ
η α σ
+
≅ −
− +
 
where η is the percentage of copy-neutral LOH contamination.   
Subsequently, a revised Gaussian mixture model (7) is derived from solely 
the remaining allelic-balanced loci. Tested on many real copy number da-
tasets, we found that the dominant component of the revised Gaussian mix-
ture distribution now corresponds to the normal copy number regions in ma-
jority of cancer types. We thus propose to rescale the measured copy number 
signal intensities using the mode of the dominant component. Since such sig-
nal normalization is performed in each individual sample and based on the 
signals of normal copy number regions, BACOM 2.0 implements an accurate 
and absolute normalization (Attiyeh, et al., 2009).   
Moreover, BACOM 2.0 includes an accurate estimation of allelic correla-
tion coefficient ρ (related to model parameter λ in defining hemi-deletion 
summery statistic) that was often underestimated due to copy-neutral LOH 
contamination. Again, by excluding copy-neutral LOH loci and identifying 
dominant normal copy regions via aforementioned scheme, we can now ob-
tain a more accurate estimate of allelic correlation coefficient ρ and subse-
quently differentiate between hemi- and homo- deletions. 
Also, we made an effort to calibrate allele signal crosstalk and saturation 
effects. Theoretically, signal crosstalk from the probes that differ only in one 
SNP adds positive bias to the copy number estimate that could lead to an 
overestimation of normal cell fraction by (6). As aforementioned, allelic 
crosstalk effect also bias the estimate of allele correlation coefficient. Con-
cerning copy number signal saturation using SNP arrays, we adopted a sim-
ilar linearization strategy used by ABSOLUTE (Carter, et al., 2012). 
Lastly, we exploited a mathematically-justified scheme to correct for the 
confounding impact of intratumor heterogeneity on estimating tumor purity 
(Oesper, et al., 2013; Rasmussen, et al., 2011). Though normal fraction α can 
hypothetically be estimated using any deletion segments, it can be experi-
mentally and theoretically shown that the value of α will highly likely be 
overestimated when intratumor heterogeneity occurs in the deletion segment 
being used. Thus, in the presence of suspected intratumor heterogeneity, only 
the ‘pure’ deletion segments with homogeneous tumor genotypes should be 
used to estimate the normal fraction. Based on the distribution of α estimates 
across the whole genome, BACOM 2.0 calculate the final value of normal 
fraction using the 9-percentile of α estimates.  
More information on BACOM 2.0 method and algorithm, summarized in 
Fig. 1, is included in Supplementary Information. 
 
Figure 1. Analytic pipeline of BACOM 2.0: schematic flowchart. 
In relation to previous work, the concept of using allele-specific infor-
mation for analyzing copy number data is shared by others (Yau, et al., 
2010), and was further developed by Rasmussen et al. (Rasmussen, et al., 
2011) for exploratory data visualization in conjunction with visual inspection 
on aneuploidy and tumor heterogeneity. There is also some similarity be-
tween our objectives and others in cancer copy number restoration and tumor 
purity estimation. The major limitations of the approach by Yuan et al. 
(Yuan, et al., 2012) are that it requires matched genomic and histopatholog-
ical image data and heavily relies on the quality of images (coarse H&E 
staining, artifacts, batch effects). ABSOLUTE developed by Carter et al. 
(Carter, et al., 2012) is supported by an elegant yet complex mathematical 
framework and can select the most likely combination of estimated tumor 
purity and ploidy by integrating copy number data and supervised learning. 
It is acknowledged that the cornerstone system of equations is underdeter-
mined and various heuristics cannot guarantee a unique and correct solution 
(Oesper, et al., 2013). For example, in the presence of intratumor heteroge-
neity, the restored copy number signals are not necessarily all integer values, 
thus using the highest likelihood of producing all integer signals to select the 
most likely solution may be problematic (Oesper, et al., 2013). PurityEst pro-
posed by Su et al. (Su, et al., 2012) estimates normal cell fraction using sin-
gle-nucleotide variants but not original sequence reads. The formulation does 
not explicitly consider effects of copy number gains/losses thus may bias 
tumor purity estimation. Moreover, PuriryEst (Su, et al., 2012), THetA 
(Oesper, et al., 2013), and AbsCN-seq (Bao, et al., 2014) rely on next-gen-
eration sequencing data, thus may not be applicable to existing copy number 
data acquired using more classic methods.                  
Intensity data annotation &
calibration
Calibrated 
intensity data
Normalized copy 
number data
Locus-specific allelic signals’ 
correlation coefficient calculation
Deletion-type 
detection
Paired 
.CEL files
Raw copy 
number data
Copy number 
calculation
Normal cell 
contamination corrected 
copy number data
Allelic Copy 
Number Signal 
Correlation 
Estimation
Segmentation
Balanced allelic signal detection
Copy-neutral component 
identification & 
genome-wide normalization
Chromosome-wise baseline 
calculation & normalization
Deletion segment 
detction
LOH detection & 
removal
Normal tissue 
fraction 
estimation
2 
BACOM 2.0 facilitates absolute normalization and quantification of somatic copy number alterations in heterogeneous tumor 
3 EXPERIMENTAL RESULTS 
3.1 Validation on realistic simulations 
We first considered numerical mixtures of simulated normal and 
cancer copy number profiles across a chromosome region, a situa-
tion in which all factors are known and linear mixture model (1) is 
valid. We reconstituted mixed copy number signals by multiplying 
the simulated cancer copy number profile by the tumor purity per-
centage in a given heterogeneous sample. The realistic simulations 
were generated using a specifically selected pair of matched tumor-
normal ovarian cancer samples in TCGA, where the tumor somatic 
copy number profile is approximately normal, i.e., allelic-balanced, 
summed copy number ‘2’, and no LOH contamination. After varia-
bly dividing the whole region into eight segments, we assigned al-
lelic-specific copy number status to each of the segments ranging 
from 0 to 3, as specified in Fig. 2. The raw copy number signals (the 
sum of the two alleles) were produced by mixing 1-α fraction of 
simulated tumor copy number profile with α fraction of normal copy 
number profile, as given in (1). This simulation represents a highly 
challenging scenario in which the majority of probe sets were not 
‘normal’ but amplified, yet also contained hemi-deletion segment 
and copy-neutral LOH segment.    
 
Figure 2. Realistic simulated allelic-specific copy number signals. 
Using BACOM 2.0 analytic pipeline, we first calculated the his-
togram of the raw copy number signals (Fig. 3a); then we prepro-
cessed the raw copy number signals by a moving-average low-pass 
filter that significantly reduced the noise effect, and re-calculated the 
histogram (Fig. 3b); lastly we eliminated all allelic-imbalanced loci 
and generated a revised histogram whose dominant peak correctly 
coincided with the normal copy number ‘2’ component (Fig. 3c).   
Table 1. Comparative parameter estimates by BACOM and BACOM 2.0 
Parameter Ground truth  BACOM  BACOM 2.0 
ρ   -0.042    -0.714   -0.063 
α   40%    79%   39% 
With a successful absolute normalization, we first checked the es-
timated value of between-allele correlation coefficient ρ, and then 
recalculated the normal cell fraction α. Based on the comparative 
estimates given in Table 1, the power of BACOM 2.0 is evident 
since the model parameter estimates were very close to the ground 
truth as compared to what obtained using original BACOM.   
 
Figure 3. (a) Histogram of simulated copy number signals; (b) Histogram 
of preprocessed copy number signals after moving-average; (c) ‘revised’ his-
togram of copy numbers after eliminating allelic-imbalanced regions. 
More information on validation design and experimental results is 
included in the supplementary information. 
3.2 Analysis of benchmark real copy number data 
We then applied BACOM 2.0 to the challenging case of TCGA 
ovarian cancer dataset (466 samples), where a high genomic insta-
bility has been well-documented in high-grade ovarian cancers 
(Kuhn, et al., 2012; Kuo, et al., 2009; Kuo, et al., 2010). We have 
observed that, in a large number of tumor samples, the dominant 
component of raw measured copy number histogram does not cor-
respond to the normal copy number ‘2’ but rather the allele-imbal-
anced loci (Fig. 4a). This observation suggests the widely existed 
partial aneuploidy in these samples, and the improper use of global 
mean/median as the normalization baseline (Attiyeh, et al., 2009).  
Using BACOM 2.0 analytic pipeline, we preprocessed the raw 
measured copy number signals by a moving-average low-pass filter, 
eliminated all allelic-imbalanced loci, generated a revised histo-
gram, and identified the component of normal copy number ‘2’ (Fig. 
4b). With a successful absolute normalization, we estimated tumor 
purity and tumor-specific copy number profile on each sample. 
From a comparison between the histogram of tumor purities likely 
underestimated by original BACOM (Fig. 4c) and the histogram of 
tumor purities newly estimated by BACOM 2.0 (Fig. 4d), we can 
see that BACOM 2.0 has now produced much higher tumor purity 
estimates (average purity of 64% versus 33%) that are theoretically 
expected and consistent with the protocol baseline adopted in inde-
pendent studies (using 50% purity as the threshold to differentiate 
between high and low tumor purity in three cancer types) (Downey, 
et al., 2014; Huijbers, et al., 2013; Su, et al., 2012). 
 
Figure 4. Analysis by BACOM 2.0 on the real TCGA ovarian cancer sam-
ples. (a) Histogram of copy number signals after moving-average prepro-
cessing; (b) Histogram of ‘revised’ copy number signals after eliminating 
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allelic-imbalanced loci; (c) Histogram of tumor purity estimated by original 
BACOM; (d) histogram of tumor purity estimated by BACOM 2.0.  
We further compared the estimates by BACOM 2.0 with the esti-
mates by ABSOLUTE (Carter, et al., 2012) on the same datasets. As 
a closely relevant method, ABSOLUTE reports the estimates of tu-
mor purity and average ploidy on two TCGA datasets, ovarian can-
cer (OV) and brain cancer (GBM). With a quality control selection 
on paired tumor and normal samples, ABSOLUTE analyzed 392 tu-
mor samples in the OV dataset. The average tumor purity estimates 
by BACOM 2.0 and ABSOLUTE are 64% and 78%, respectively; 
and the average tumor ploidy estimates by BACOM 2.0 and 
ABSOLUTE are 2.33 and 2.73, respectively. The sample-wise cor-
relation coefficients show that both tumor purity and tumor ploidy 
estimates by BACOM 2.0 correlate well with the estimates by 
ABSOLUTE (Fig. 5), achieving a high correlation coefficient of r = 
0.74 on purity and a high correlation coefficient of r = 0.71 on 
ploidy. On the GBM dataset, the average tumor purity estimates by 
BACOM 2.0 and ABSOLUTE are 59% and 71%, respectively; and 
the average tumor ploidy estimates by BACOM 2.0 and 
ABSOLUTE are 2.09 and 2.17, respectively.   
 
Figure 5. Sample-wise comparison between the estimates of tumor purity 
and average ploidy by BACOM 2.0 and ABSOLUTE on TCGA ovarian can-
cer samples. (a) Scatter plot of tumor purity estimates; (b) Scatter plot of 
tumor ploidy estimates.     
More information on additional experimental results (tables and 
figures) is included in the supplementary information. 
3.3 Cross-affirmation by expression deconvolution  
In the absence of definite ground truth about the tumor purities in 
real samples, the validation of a new method for quantifying abso-
lute copy numbers is always problematic. A reasonable alternative 
is to perform some form of ‘cross’ affirmation by exploiting the ‘or-
thogonal’ information structures provided by the independent 
sources related to a common set of nature states (Niv Ahituv and 
Ronen, 1988). We lastly compared the tumor purity estimates by 
BACOM 2.0 with the estimates by an independent method (called 
UNDO) that deconvoluted the mixed gene expression profiles of tu-
mor and stroma cells acquired from the same TCGA OV samples 
(Wang, et al., 2013). Using the UNDO software, we analyzed the 
tumor samples with consistent purity estimates by both BACOM 2.0 
and ABSOLUTE. The experimental result shows that the tumor pu-
rity estimates by BACOM 2.0 (based on copy number data) corre-
lates well with the estimates by UNDO (based on gene expression 
data), consistently achieving a strong average ‘cross’ correlation co-
efficient of 0.5~0.6 in multiple runs.  
The imperfect ‘cross’ correlation between the tumor purity esti-
mates by BACOM 2.0 and UNDO is expected because the two 
methods use different molecular data types, where copy number val-
ues are always ‘2’ across all normal cells (e.g., stroma, T-cells, mon-
ocytes) while gene expression values are cell type specific. In fact, 
there are multiple gene expression profiles corresponding to various 
normal cells. Moreover, copy number values are generally ‘static’, 
while gene expression values are intrinsically ‘dynamic’.  
4 DISCUSSION 
In this letter, we corrected and extended the BACOM method of 
Yu et al. (Yu, et al., 2011) to more accurately detect deletion types, 
estimate normal cell fraction, and quantify true copy numbers in tu-
mor cells. We achieved these objectives by introducing a more com-
prehensive signal modeling and absolute normalization scheme 
(Attiyeh, et al., 2009). BACOM 2.0 offers several attractive fea-
tures: (1) It performs absolute normalization by identifying the nor-
mal copy number component in a ‘revised’ Gaussian mixture histo-
gram; (2) It estimates signal models and their parameter values after 
eliminating significant confounding factors; (3) It calculates the 
overall normal cell fraction (or tumor purity) with a correction for 
potential intratumor heterogeneity; and (4) It adjusts the effect of 
copy number signal saturation.                
Fundamental to the success of our approach is the rigorous signal 
modeling and absolute normalization. In the presence of both nor-
mal cell contamination and tumor aneuploidy, with proper sample 
quality control (Popova, et al., 2009), our experience indicates that 
absolute normalization can be done separately (or iteratively) from 
tumor purity/ploidy estimation (Attiyeh, et al., 2009).  We expect 
BACOM 2.0 to be a useful tool for analyzing copy number data in 
heterogeneous tumor samples (Zhang, et al., 2014), complement to 
the existing methods (Carter, et al., 2012; Oesper, et al., 2013). 
Since BACOM 2.0 is supported by a well-grounded and unambig-
uous statistical framework, we foresee a variety of extensions to the 
concepts and strategies here. Regarding the detection of allelic-im-
balanced loci, a good alternative to allelic correlation coefficient is 
the B allele frequency ratio (Attiyeh, et al., 2009; Popova, et al., 
2009; Van Loo, et al., 2010). When there are multiple deletion seg-
ments across genome, the distribution of α estimates merits some 
further study since it may indicate the presence of intratumor heter-
ogeneity defined by subclone copy number aberrations. Moreover, 
with further development, localized chromosomal ploidy can be de-
tected instead of average tumor ploidy (Van Loo, et al., 2010).  
Though a significant sample-wise correlation between the tumor 
purity estimates by BACOM 2.0 and ABSOLUTE has been ob-
served, further investigation into the discrepancy between the aver-
age tumor purity estimates by the two methods would be interesting, 
given the fact that no definite ground truth is available. For example, 
TCGA used 60~80% tumor purity as the threshold to select tumor 
samples and a protocol baseline of 50% tumor purity was adopted 
to differentiate between high and low tumor purity in three cancer 
types (Downey, et al., 2014; Huijbers, et al., 2013; Su, et al., 2012), 
while rather poor correlations were reported between the estimates 
by ABSOLUTE/ESTIMATE and histological method probably due 
to miscount of infiltrating immune cells in pathological examina-
tions (Yoshihara, et al., 2013).                 
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